about
Editorial of Special Issue Ruthenium Complex: The Expanding Chemistry of the Ruthenium ComplexesCytotoxic properties of a new organometallic platinum(II) complex and its gold(I) heterobimetallic derivatives1H HR-MAS NMR Based Metabolic Profiling of Cells in Response to Treatment with a Hexacationic Ruthenium Metallaprism as Potential Anticancer DrugThe elements of life and medicinesColorectal Carcinoma: A General Overview and Future Perspectives in Colorectal CancerAnionic chlorido(triphenyl)tin(IV) bearing N-phthaloylglycinato or 1,2,4-benzenetricarboxylato 1,2-anhydride ligands: potential cytotoxic and apoptosis-inducing agents against several types of cancer.Chronic treatment with cisplatin induces chemoresistance through the TIP60-mediated Fanconi anemia and homologous recombination repair pathways.GLUT1-mediated selective tumor targeting with fluorine containing platinum(II) glycoconjugatesChronic treatment with cisplatin induces replication-dependent sister chromatid recombination to confer cisplatin-resistant phenotype in nasopharyngeal carcinoma.Communication: Photoactivation of nucleobase bound platinum(II) metal complexes: probing the influence of the nucleobase.Hydrous RuO2 nanoparticles as an efficient NIR-light induced photothermal agent for ablation of cancer cells in vitro and in vivo.Anticancer Gold(III) Porphyrins Target Mitochondrial Chaperone Hsp60.Potent organo-osmium compound shifts metabolism in epithelial ovarian cancer cells.Polymeric Micelle-Mediated Delivery of DNA-Targeting Organometallic Complexes for Resistant Ovarian Cancer Treatment.Ruthenium(II) Complexes with 2-Phenylimidazo[4,5-f][1,10]phenanthroline Derivatives that Strongly Combat Cisplatin-Resistant Tumor CellsNovel enantiopure cyclopentadienyl Ti(IV) oximato compounds as potential anticancer agents.New bipyridine gold(III) dithiocarbamate-containing complexes exerted a potent anticancer activity against cisplatin-resistant cancer cells independent of p53 statusDeveloping an anticancer copper(II) pro-drug based on the nature of cancer cell and human serum albumin carrier IIA subdomain: mouse model of breast cancer.Antiproliferative effects of ruthenium-based nucleolipidic nanoaggregates in human models of breast cancer in vitro: insights into their mode of action.DNA or protein? Capillary zone electrophoresis-mass spectrometry rapidly elucidates metallodrug binding selectivity.Is matching ruthenium with dithiocarbamato ligands a potent chemotherapeutic weapon in oncology?The mitochondrial apoptotic pathway is induced by Cu(II) antineoplastic compounds (Casiopeínas®) in SK-N-SH neuroblastoma cells after short exposure times.Evaluation of functionalized mesoporous silica SBA-15 as a carrier system for Ph3Sn(CH2)3OH against the A2780 ovarian carcinoma cell line.Studies on Photocleavage, DNA Binding, Cytotoxicity, and Docking Studies of Ruthenium(II) Mixed Ligand Complexes.Dual-drug loaded nanoformulation with a galactosamine homing moiety for liver-targeted anticancer therapy.Specific Design of Titanium(IV) Phenolato Chelates Yields Stable and Accessible, Effective and Selective Anticancer Agents.Synthesis and biological evaluation of novel platinum complexes of imidazolyl-containing bisphosphonates as potential anticancer agents.Highly Stable Tetra-Phenolato Titanium(IV) Agent Formulated into Nanoparticles Demonstrates Anti-Tumoral Activity and Selectivity.In vitro and in vivo evaluation of organometallic gold(I) derivatives as anticancer agents.Influence of reducing agents on the cytotoxic activity of platinum(IV) complexes: induction of G2/M arrest, apoptosis and oxidative stress in A2780 and cisplatin resistant A2780cis cell lines.Lipophilicity-dependent ruthenium N-heterocyclic carbene complexes as potential anticancer agents.Synthesis, characterization and urease inhibition, in vitro anticancer and antileishmanial studies of Ni(II) complexes with N,N,N'-trisubstituted thioureas.Synthesis and anticancer activities of a novel class of mono- and di-metallic Pt(II)(salicylaldiminato)(DMSO or Picolino)Cl complexes.Designing metallodrugs with nuclease and protease activity.Schiff bases in medicinal chemistry: a patent review (2010-2015).Imidazolium and benzimidazolium-containing compounds: from simple toxic salts to highly bioactive drugs.The development of anticancer ruthenium(ii) complexes: from single molecule compounds to nanomaterials.Biological properties of novel ruthenium- and osmium-nitrosyl complexes with azole heterocycles.Highly active group 11 metal complexes with α-hydrazidophosphonate ligands.Protein staining agents from low toxic platinum(ii) complexes with bidentate ligands.
P2860
Q26782380-0014DF2B-DD0F-4DB7-A7F8-072EBA5CB4D4Q27702884-599F3028-5D8D-4430-AFB7-0703D91D6275Q28547627-68D236CF-29DA-413F-B3C5-80A533AE3BBDQ28649323-A9DCEC25-0AE0-44ED-9A20-98FF15B4D1C8Q30238915-C346C987-1715-4632-84E7-64F92A476060Q30313823-CF44E9AA-1E87-4D03-996A-CE4984F720CCQ33818857-F3866031-0283-4DA4-B424-165FCDB85744Q33889236-E47DF07A-845F-446D-9A31-67868290E51EQ34227706-D0CA28E3-FF85-4974-9BC8-65E4F72EC5F2Q35536915-698BCB3E-A023-4728-9200-886ACBEFA4DEQ35657419-688A6B6F-DAAB-45A0-BB71-5EE66A539D0DQ35867952-16F70AE6-0F6A-4EE4-B88B-E209FC9C7623Q35895492-A88474E1-615C-409B-BA04-44D81E8D30AEQ36253687-0B7AA40B-E70D-44EA-9A73-E0DAC4228E47Q36499563-BC051918-D9AF-4328-A202-A57A4BB8A8A2Q36942237-5DA2A2EC-AF7A-4E6C-9F78-30B97B48E2B3Q37686897-012CAC35-E4B8-41F3-9B44-47EFED7AA091Q37687110-5C69CD64-CFEA-4146-8F4E-5349634EE618Q37724010-B4311D26-FE9A-41A0-8035-F46E693696ADQ38287806-CB0BE055-430D-414D-A7C0-2E5F795C2B40Q38710506-EF68E1AB-FD64-4FB1-8419-DDDCA56B06BCQ38725601-A3B49DD1-0DD7-45F2-9E5E-DE002EE9FB3DQ38730893-A3D5EF8A-8E97-40B2-B25A-BF6875CBD069Q38735217-D798E8E4-2E4D-4C72-9A52-A02BCCA2C3A0Q38762779-63C12F11-CB69-4B64-B9BB-39B095C6C23CQ38763409-DCF1A2FD-EA36-408E-825E-4B31A9EE635DQ38822283-2548FE13-72EC-4830-B320-1A72BBBEBC8DQ38827449-F797BA3C-9F77-40D8-92B3-BCDF339522FFQ38827745-796D4BD0-E8D0-470D-BC9D-5894F39EC23EQ38864172-289F828B-7F45-47C6-AAE1-0B0448D87850Q38896547-93058D0E-C692-46D1-B7D9-C412704933B6Q38918255-A4DF9BC7-1973-4B0D-91F4-09C29FEC02BAQ38928386-5D335A33-E9DB-47EA-8DE7-9895B0B879CAQ38974558-8359C2CC-6DCD-474D-987D-726016361D7EQ38989218-B4AF9066-C0B3-4316-A956-E23753F7CEDDQ39065508-33368CC9-E531-47CF-A993-3AFAABFA97C6Q39400527-108893B0-AD6C-483C-8643-65F84C2297F9Q40786041-0A03D508-DB66-4A3E-AEBB-AF4D301DAB8CQ46299572-0CC7B2B5-A886-4ACC-B7BF-942C9D4F76AAQ47251134-BDA294DA-0362-4FCE-89C8-117E7D61926D
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Metal-based anticancer chemotherapeutic agents.
@en
type
label
Metal-based anticancer chemotherapeutic agents.
@en
prefLabel
Metal-based anticancer chemotherapeutic agents.
@en
P1476
Metal-based anticancer chemotherapeutic agents.
@en
P2093
Nafees Muhammad
Zijian Guo
P304
P356
10.1016/J.CBPA.2014.02.003
P577
2014-03-05T00:00:00Z